Cartesian Therapeutics (RNAC) Financials

Cartesian Therapeutics (NASDAQ: RNAC) remains a development-stage company with limited operating revenue and substantial cash needs. The latest quarter showed a sharp improvement in reported net income, but that result was driven primarily by non-operating income rather than recurring business activity.

• Cash increased significantly in Q2 2026. Cash and equivalents rose to $147.6 million from $118.6 million in Q1, a $29.0 million increase. The improvement was primarily supported by $50.3 million of financing proceeds.
• Quarterly operating cash burn improved modestly. Net cash used in operating activities declined to $21.1 million in Q2 2026 from $22.1 million in Q1 and $22.1 million in Q2 2025. Based solely on the latest cash balance and quarterly operating burn, the company has a meaningful cash cushion, although future financing needs remain likely.
• Reported profitability improved sharply on a sequential basis. RNAC reported $15.8 million of consolidated net income and $13.7 million attributable to common shareholders in Q2 2026, compared with a $39.2 million net loss in Q1. Diluted earnings per share improved to $0.46 from a loss of $1.46.
• Research and development spending continues to support the company’s pipeline. R&D expense increased to $20.4 million in Q2 2026 from $19.5 million in Q1, indicating that Cartesian continues to invest heavily in clinical and development activities.
• Liquidity is concentrated in cash rather than operating assets. Cash represented approximately 96% of current assets at the end of Q2 2026. Accounts receivable were only $196,000, while prepaid expenses were $5.8 million, reflecting the company’s limited commercial activity.
• Q2’s net income was heavily influenced by non-operating items. Revenue was zero and operating expenses totaled $29.2 million, producing a $29.2 million operating loss. A $44.7 million gain classified as other income drove the company to a pretax profit, making the quarter’s earnings less representative of recurring operating performance.
• Revenue generation has deteriorated materially. Operating revenue declined from $33.4 million in Q2 2024 and $298,000 in Q2 2025 to zero in Q2 2026. Without meaningful product or partnership revenue, the company remains dependent on external financing and cash reserves.
• Operating expenses continue to exceed revenue by a wide margin. Total operating expenses rose from $22.1 million in Q2 2025 to $29.2 million in Q2 2026, while revenue fell to zero. R&D accounted for $20.4 million of the latest quarter’s spending, with SG&A adding $8.7 million.
• Shareholder dilution is an ongoing risk. RNAC issued $3.9 million of common equity in Q2 2026 and $15.4 million in Q1. Weighted average diluted shares increased to 29.9 million in Q2 2026 from 26.4 million in Q2 2025, a rise of roughly 13%.
• The balance sheet shows negative book equity and significant liabilities. Total liabilities were $443.9 million versus total equity of negative $125.2 million at June 30, 2026. Other noncurrent operating liabilities alone were reported at $363.5 million, while retained earnings stood at a deficit of $845.8 million. These figures indicate substantial accumulated losses and balance-sheet risk.

Overall, RNAC’s Q2 2026 statements present a mixed picture. The company strengthened its cash position through financing and reduced its quarterly operating burn slightly, but it still has no reported operating revenue, continues to incur sizable research expenses, and remains reliant on capital markets. Investors should distinguish the quarter’s accounting profit from sustainable operating profitability and monitor cash usage, financing activity, dilution and progress toward revenue-generating milestones.